WOMEN'S HEALTH
hamburger
BACK
Early pregnancy

EARLY
PREGNANCY

DUPHASTON® IS INDICATED TO HELP WOMEN IN REDUCING THE RISK OF MISCARRIAGE IN EARLY PREGNANCY.1

Early pregnancy is a delicate period. Sometimes unexpected events such as the risk of miscarriage may happen. Most miscarriage occurs in the first 13 weeks of pregnancy and the risk continues up to 24 weeks.2

Providing luteal phase support with progestational agents is essential to facilitate egg implantation in an early pregnancy.1

Duphaston® has shown to reduce the risk of threatened and recurrent miscarriage.3-8

INDEPENDENT SYSTEMATIC REVIEWS SUPPORT DUPHASTON® EFFICACY3-11

Threatened Miscarriage

Recurrent Miscarriage

RECOMMENDED

Menstrual disorders

Menstrual Disorders

Endometriosis

Endometriosis

Mother Daughter

Please see accompanying

PRESCRIBING INFORMATION

 

1. Abbott Laboratories. Registered HK Package insert. May 2008.

2. Neilson J, Gyte G, Hickey M, Vazquez J, and Dou L. Medical treatments for incomplete miscarriage (less than 24 weeks) Cochrane Database Syst Rev. ; (1): CD007223.

3. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009;65(Suppl 1):S47–S50.

4. Wahabi HA, Fayed AA, Esmaeil SA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2007;(3):CD005943.

5. Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011;(12):CD005943.

6. El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas 2009;65(Suppl 1):S43–S46.

7. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28(12):983–990.

8. Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2018 Aug 7;8:CD005943. doi: 10.1002/14651858.CD005943.pub5. [Epub ahead of print] Review. PubMed PMID: 30081430.

9. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2013;(10):CD003511.

10. Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015; 31(6):422–430.

11. Saccone G, Schoen C, Franasiak JM, et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017 Feb;107(2):430-438.e3.

 

Abbott Logo

© 2018 Abbott. All Rights Reserved. Please read the Terms of Use for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.

No use of Abbott trademarks, trade name, or trade dress in this site may be used without the written authorization of Abbott, except to identify the product or services of the company.

The information on this website is only intended for use by Healthcare Professionals in Hong Kong.  The information on the drugs in this website may differ from the drugs available in other countries.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2018 Abbott. All Rights Reserved. Please read the Terms of Use for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.

No use of Abbott trademarks, trade name, or trade dress in this site may be used without the written authorization of Abbott, except to identify the product or services of the company.

The information on this website is only intended for use by Healthcare Professionals in Hong Kong. The information on the drugs in this website may differ from the drugs available in other countries.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO
accessibility
© 2018 Abbott. All Rights Reserved. Please read the Terms of Use for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.

No use of Abbott trademarks, trade name, or trade dress in this site may be used without the written authorization of Abbott, except to identify the product or services of the company.

The information on this website is only intended for use by Healthcare Professionals in Hong Kong. The information on the drugs in this website may differ from the drugs available in other countries.

YESNO
accessibility

Are you an Health-Care Professional ?

The information in this section is intended only for healthcare professionals of Pakistan. If you are a healthcare professional, click "I Agree" to continue.

YES NO